Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration
Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S, Group O. Superiority of Icodextrin Compared with 4.25% Dextrose for Peritoneal Ultrafiltration. Journal Of The American Society Of Nephrology 2004, 16: 546-554. PMID: 15625070, DOI: 10.1681/asn.2004090793.Peer-Reviewed Original ResearchConceptsIcodextrin groupNegative net ultrafiltrationNet ultrafiltrationPeritoneal ultrafiltrationWeek 2Week 1Control groupDouble-blind trialPercentage of patientsAutomated Peritoneal DialysisPeritoneal dialysisTreatment groupsControlled EvaluationHigh transportersClinical observationsIcodextrinStudy periodBaselineLong dwellPatientsDextroseSolute removalGroupEfficiency ratioMulticenterCinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. New England Journal Of Medicine 2004, 350: 1516-1525. PMID: 15071126, DOI: 10.1056/nejmoa031633.Peer-Reviewed Original ResearchConceptsParathyroid hormone levelsPrimary end pointSecondary hyperparathyroidismHormone levelsPlacebo groupCinacalcet groupLow parathyroid hormone levelsSerum calcium-phosphorus productIntact parathyroid hormone levelsEnd pointCalcium-phosphorus productEfficacy assessment phaseParathyroid hormone valuesPatients Receiving HemodialysisPlacebo-controlled trialPercentage of patientsAdverse clinical outcomesCalcium-phosphorus homeostasisCalcium-sensing receptorClinical outcomesVitamin DDaily dosesStandard treatmentHormone valuesCardiovascular disease